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A B S T R A C T
The potential neuroprotective beneﬁts of curcumin against cisplatin neurotoxicity were investigated.
Curcumin is a polyphenol derived from the rhizome of Curcuma longa whose pharmacological effects
include antioxidant, anti-inﬂammatory and anti-cancer properties. Cisplatin is a potent chemothera-
peutic drug with activity against a wide variety of tumors, although it has notorious side effects. Cisplatin
neurotoxicity is clinically evident in patients that have undergone a full course of chemotherapy and
develop a peripheral neuropathy that may affect the treatment regimen and the patient’s qualify of life.
In this study, we examined whether curcumin can protect against cisplatin neurite outgrowth inhibition
in PC12 cells, which is an indicator of the protective potential against neuropathy. We also investigated
whether curcumin affects cisplatin effectiveness by analyzing the modulation of p53 gene expression
and its effect on cisplatin cytotoxicity in HepG2 tumor cells. Non-cytotoxic concentrations of curcumin
reduced in vitro neurotoxicity of cisplatin in PC12 cells. The treatment of PC12 cells with cisplatin (10 mg/
mL) signiﬁcantly reduced neurite outgrowth. The tested concentration of curcumin (1.0 and 10 mg/mL)
did not result in neurite toxicity but nevertheless diminished cisplatin-induced inhibition of neurite
outgrowth by up to 50% (p < 0.05). Our results indicate that curcumin does not compromise cisplatin’s
anticancer activity. Curcumin neither suppressed p53 mRNA transcription nor protected tumor cells
against cisplatin cytotoxicity. These results indicate that curcumin may reduce cisplatin-induced
neurotoxicity, and clinical studies should potentially be considered.
 2012 Elsevier Inc. 
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Curcumin (diferuloylmethane) is a yellow pigment derived
from the rhizome of Curcuma longa. Turmeric, the dried ground
rhizome of C. longa, is a spice employed as a ﬂavoring and coloring
agent in many food preparations. Additionally, turmeric has been
used for thousands of years in Ayurvedic and Chinese medicine.
Curcumin is a polyphenol that is recognized as the main
biologically active compound in turmeric and is responsible for
its medical beneﬁts (Goel et al., 2008; Sharma et al., 2005).
The safety of curcumin has been widely demonstrated,
and curcumin has a variety of potential pharmaceutical
applications. Curcumin exhibits antioxidant, anti-inﬂammatory
and anticancer properties and has been described as neuropro-
tective against neurological disorders (Aggarwal and Harikumar,* Corresponding author at: Faculdade de Cieˆncias Farmaceˆuticas de Ribeira˜o
Preto-USP, Departamento de Ana´lises Clı´nicas, Toxicolo´gicas e Bromatolo´gicas, Av.
do Cafe´ s/n – Bairro Monte Alegre, Ribeira˜o Preto 14040-903, SP, Brazil.
Tel.: +55 16 3602 4294; fax: +55 16 3602 4725.
E-mail address: leonardo.meneghin@gmail.com (L.M. Mendonc¸a).
0161-813X       2012 Elsevier Inc. 
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Open access under the Elsevier OA license. 2009; Maheshwari et al., 2006). Curcumin’s antioxidant capacity
is similar to other potent antioxidants, such as trolox (a vitamin E
analog) (Somparn et al., 2007). Curcumin inhibits lipid peroxi-
dation in different tissues, regulates intracellular levels of
antioxidant enzymes (e.g., catalase, glutathione peroxidase and
superoxide dismutase) and is an effective intracellular reactive
oxygen species (ROS) scavenger (Barzegar and Moosavi-Mova-
hedi, 2011; Soobrattee et al., 2005; Sreejayan and Rao, 1994).
Many of curcumin’s pharmacological beneﬁts arise from its
antioxidant or anti-inﬂammatory properties. Curcumin appears to
have signiﬁcant potential for treatment of diseases that result from
oxidative stress (Aggarwal and Harikumar, 2009). Reports have
shown that curcumin possesses protective effects in different
neuronal cell lines and tissues. Curcumin has neuroprotective
actions in Alzheimer’s disease, multiple sclerosis, Parkinson’s
disease, epilepsy, and other neurodegenerative disorders that may
be related to oxidative stress (Kulkarni and Dhir, 2010; Wang et al.,
2010; Xie et al., 2011).
Chemotherapy-induced peripheral neuropathy is a common
and incapacitating adverse effect of chemotherapy that may be
caused by oxidative stress. Many chemotherapeutic agents,
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produce this adverse effect (Jaggi and Singh, 2012). Cisplatin has
been widely used in chemotherapy for nearly 40 years; however,
its effectiveness may be limited due to adverse effects, such as
peripheral neuropathy (Kelland, 2007; Pace et al., 2010). Patients
completing a full course of platinum-based anticancer drugs often
develop clinically detectable sensory peripheral neuropathies.
Peripheral neuropathy results from cisplatin neurotoxicity, which
can be severe and signiﬁcantly affect the patient’s quality of life
(Brouwers et al., 2009; Siegal and Haim, 1990).
Cisplatin’s antitumor mode of action is mediated by its direct
interaction with DNA; cisplatin forms adducts, which activate
several signal transduction pathways, such as those involving the
p53 protein, that culminate in the activation of apoptosis in rapidly
dividing tumor cells (Ma et al., 2008; Siddik, 2003). However, the
exact mechanism of cisplatin neurotoxicity in post-mitotic
neurons is not completely understood, although it seems to
involve axonal integrity loss in sensory neurons (James et al., 2010;
Ozturk et al., 2004). The post-mitotic sensory neurons of the dorsal
root ganglia (DRG) are particularly susceptible to cisplatin damage.
Studies in DRG neurons have produced evidence that axonal injury
involves multiple events that include ROS generation, suggesting
that antioxidants might be useful in reducing cisplatin neurotox-
icity (Carozzi et al., 2010; McDonald et al., 2005).
It is not known whether the neuroprotective effects of curcumin
could be extended to cisplatin-induced neurotoxicity. To investi-
gate this question, the neuroprotective effects of curcumin were
evaluated in an in vitro model using PC12 cells. This cell line was
developed from an adrenal gland pheochromocytoma. PC12 cell is
responsive to nerve growth factor (NGF), which causes differenti-
ation into sympathetic-like neurons (Tischler and Greene, 1978).
Differentiated PC12 cells are useful for neurotoxicity studies once
they have a number of neuronal characteristics. PC12 cell
differentiation includes development of synaptic-like vesicles,
increased electrical excitability, cessation of mitosis and the
development of neurite extensions (Green, 1995).
We evaluated the potential of curcumin to reduce cisplatin
neurotoxicity using a neurite outgrowth assay that has been
proposed for in vitro investigations of chemotherapy-induced
peripheral neuropathy; in this assay, cisplatin causes a dose-
dependent reduction of NGF-dependent neurite formation (Geldof
et al., 1998; Klein et al., 2007; Takeshita et al., 2011; Verstappen
et al., 1999, 2004). Cisplatin has been used widely as a
chemotherapeutic drug for a variety of malignancies including
hepatocellular carcinoma (Zhang et al., 2001). Thus, we also
investigated whether curcumin affects cisplatin antitumor effec-
tiveness by analyzing the effect of curcumin on cisplatin
cytotoxicity in the human hepatocellular liver carcinoma cell line
(HepG2), and the importance of the modulation of p53 gene
expression in the neuroprotective effects of curcumin.
2. Materials and methods
2.1. Chemicals
Curcumin was provided by the Industrial Physics Laboratory of
the FCFRP-USP. Cisplatin was purchased from Quiral Quı´mica do
Brasil (Platinil1, Juiz de fora, Brazil). Nerve growth factor (NGF)
and mouse laminin puriﬁed protein were purchased from
Millipore (Billerica, MA, USA). Dimethylsulfoxide was purchased
from Merck (Darmstadt, Germany). RPMI 1640 and DMEM culture
medium, fetal bovine serum, horse serum and penicillin/strepto-
mycin antibiotic mixtures were purchased from GibcoTM (Carls-
bad, CA, USA). Other reagents were of analytical grade and the
purest quality available.2.2. Cells
Undifferentiated PC12 cells (Cat. No. CRL-1721) and HepG2 cells
(Cat. No. HB-8065), obtained from the American Type Culture
Collection (Rockville, MD, USA), were cultured in 75-cm2 ﬂasks in a
humidiﬁed incubator in a atmosphere of 95% air and 5% CO2 at
37 8C (Thermo Electron Co.). Undifferentiated PC12 cells were
cultivated in RPMI 1640 liquid medium supplemented with 10%
horse serum, 5% fetal bovine serum and a penicillin/streptomycin
antibiotic mixture. HepG2 cells were cultivated in DMEM with 15%
fetal bovine serum and a penicillin/streptomycin antibiotic
mixture. For both cell lines, the media were changed every 3–4
days, and cells were passaged when they reached 80–90%
conﬂuence. In all experiments, undifferentiated PC12 and HepG2
cells were used between the 3rd and 10th passage.
2.3. MTT assay
The MTT assay (Mosmann, 1983) was performed to evaluate
cytotoxicity in PC12 and HepG2 cells. PC12 cells were evaluated in
undifferentiated (PC12) and NGF-differentiated (dPC12) states.
Before performing the MTT assay, PC12 cells were differentiated
for 72 h of incubation in differentiation medium. The cell cultures
were exposed to serial dilutions of curcumin or cisplatin in
preliminary experiments to establish the studied concentrations
(data not shown). PC12 cells and dPC12 were plated in 96-well
plates (1.0  105 cells/mL) with 100 mL of medium, and cisplatin
(5.0 or 10 mg/mL), curcumin (0.1, 1.0 or 10 mg/mL) and combina-
tions thereof were added to each well. HepG2 cells were plated in
96-well plates (0.5  105 cells/mL) with 100 mL of medium and
then treated with cisplatin (10 mg/mL) alone or co-incubated with
curcumin (0.1, 1.0 or 10 mg/mL). After 24 h of treatment, the plates
were incubated with 10 mL of MTT solution (0.5 mg/mL) for 3 h.
The medium was then removed, and the purple formazan crystals
were dissolved in 100 mL of dimethylsulfoxide. The absorbance of
each well was measured at 570 nm by a microplate reader (Biotek,
EL800). Cell viabilities are expressed as the percentage of the mean
optical density value from the negative control wells.
2.4. Neurite outgrowth assay
The neurite outgrowth assay was conducted with the Chemi-
con’s NS225 kit according to the manufacturer’s instructions
(Millipore, Billerica, MA, USA). Prior to the initiation of the neurite
outgrowth assay, undifferentiated PC12 cells were incubated in
differentiation medium consisting of RPMI 1640 + 1% horse
serum + 1% penicilin/streptomycin + 100 ng/mL NGF for 72 h for
cell priming. After priming, the cells (100 mL of 1.0  106 cell/mL)
were transferred to a cell culture insert (previously coated with
puriﬁed mouse laminin protein) containing permeable membrane
pores that passed through the base, which allowed distinction of
neurites and cell bodies. The cell culture inserts were placed into
culture plate wells containing the differentiation medium with the
tested substances. The cells were then treated with cisplatin
(10 mg/mL) and curcumin (1.0 or 10 mg/mL) or both curcumin and
cisplatin together. For cotreatment treatment, cisplatin was
removed after 24 h, and the cultures were then treated with
curcumin for an additional 48 h. The optimal treatment concen-
trations of cisplatin for causing neurite damage have been
previously evaluated (Klein et al., 2007). The tested concentrations
of curcumin and cisplatin used in the neurite outgrowth assay
were evaluated with the MTT assay with differentiated PC12 cells
and did not produce considerable cytotoxicity. After the treatment
period, cell cultures were washed, ﬁxed, neurite stained, stain
extracted and stain solution extracted was quantiﬁed at 562 nm,
according to the manufacturer’s protocol.
Fig. 1. MTT assay of the human hepatocellular liver carcinoma cell line (HepG2)
treated with cisplatin alone or in combination with curcumin. CMN = curcumin and
cDDP = cisplatin. Bars indicate the means  standard deviations obtained from three
independent cultures made in parallel. *Signiﬁcant difference compared with the
negative control (p < 0.05), as measured by one-way ANOVA followed by Tukey’s post
hoc test.
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Total RNA was extracted from PC12 cells after treatment for
48 h with non-cytotoxic concentrations of cisplatin (0.1 mg/mL),
curcumin (5.0 mg/mL), or curcumin combined with cisplatin. The
non-cytotoxic concentrations of cisplatin and curcumin in undif-
ferentiated PC12 cells were obtained from our previously published
data (Mendonca et al., 2009). Total RNA extraction was performed
using the SV total RNA isolation system (Promega, Madison, WI,
USA) according to the manufacturer’s instructions. The quality and
integrity of the extracted RNA were assessed by both gel
electrophoresis in 1.0% agarose and the ratios of the spectrophoto-
metric optical density measurements at 260 nm/280 nm and
260 nm/230 nm. The extracted RNA was converted to cDNA using
the kit SuperScriptTM III (Invitrogen, Carlsbad, CA, USA). The PCRs
were performed using the Biorad Real-Time PCR system with the
ABsoluteTM QPCR SYBR1 Green Mix kit (Invitrogen, Carlsbad, CA,
USA) with gene-speciﬁc primers for p53 (p53-forward: CATCAT-
CACGCTGGAAGACTC; p53-reverse: TTCAGCTCTCGGAACATCTC) and
b-actin (b-actin-forward: TCCTGTGGCATCCATGAACT; b-actin-
reverse: CCAGGGCAGTAATCTCTTTCTTCTG). A negative control
without the RNA template was also included. The relative expression
of p53 mRNA was normalized to the amount of b-actin mRNA using
the 2DDct relative quantiﬁcation method.
2.6. Data analysis
Each experiment was performed three times, and the values are
expressed as the means  the standard deviations. Group compar-
isons in the neurite outgrowth assay were made using paired t-tests,
and other results were analyzed using one-way ANOVA followed by
Tukey’s post hoc test. Statistical analysis was performed with the
GraphPad Prism 5.0 software. Differences were considered signiﬁcant
at p < 0.05.
3. Results
3.1. MTT assay
The MTT assay was performed in PC12 and HepG2 cells to
evaluate cell viability after different treatments. The viability of the
cultures was determined by establishing the relationship between
the absorbances obtained in the treated and untreated (negativeTable 1
MTT assay of undifferentiated and differentiated PC12 cells treated with curcumin,
cisplatin or a combination of both compounds for 24 h.
Treatments (mg/mL) % cell viability
Undifferentiated
PC12 cells
Differentiated
PC12 cells
Negative control 100  0 100  0
CMN 0.1 99  4 83  11
CMN 1.0 88  7 83  9
CMN 10 67  14* 80  5
cDDP 5 74  1 80  12
cDDP 5 + CMN 0.1 79  16 79  8
cDDP 5 + CMN 1.0 74  17 78  14
cDDP 5 + CMN 10 52  6* 81  11
cDDP 10 58  5* 73  3
cDDP 10 + CMN 0.1 63  10* 74  8
cDDP 10 + CMN 1.0 54  14* 86  12
cDDP 10 + CMN 10 45  1* 85  18
CMN, curcumin; cDDP, cisplatin.
The results were obtained from three independent cultures obtained in parallel.
* p < 0.05 compared with the negative control, as measured by one-way ANOVA
followed by Tukey’s post hoc test.control) groups. The negative control was considered to have 100%
cell viability.
Undifferentiated and differentiated PC12 cells were treated
with curcumin (0.1, 1.0 or 10 mg/mL), cisplatin (5.0 or 10 mg/mL)
or combinations of both compounds for 24 h, and the cell viability
results are presented in Table 1. We did not observe a
cytoprotective effect of curcumin against cisplatin cytotoxicity
in undifferentiated or differentiated PC12 cells. Neither curcumin
nor cisplatin, alone or combined, signiﬁcantly affected the cell
viability of differentiated PC12 cells.
Undifferentiated PC12 cells were more sensitive to cisplatin and
curcumin than differentiated PC12 cells. A signiﬁcant cellular
viability reduction was observed in the undifferentiated PC12 cells
treated with cisplatin or curcumin at the concentration of 10 mg/
mL (p < 0.05). Combination with curcumin (0.1, 1.0 or 10 mg/mL)
did not protect these cells from cisplatin cytotoxicity.
We also performed the MTT assay in HepG2 cells to evaluate
whether curcumin affects cisplatin cytotoxicity in tumor cells. The
HepG2 cells were treated with cisplatin 10 mg/mL alone or co-
incubated with curcumin (0.1, 1.0 or 10 mg/mL) for 24 h.
Cisplatin was signiﬁcantly cytotoxic to HepG2 cells (Fig. 1).
Furthermore, cisplatin at 10 mg/mL was more cytotoxic in HepG2
cells than in undifferentiated PC12 cells. The treatment of HepG2
cells with cisplatin (10 mg/mL) reduced cell viability by approxi-
mately 70%, and curcumin did not protect these cells from cisplatin
cytotoxicity. Co-incubation with curcumin (0.1, 1.0 or 10 mg/mL)
also resulted in an approximately 70% reduction in cell viability.
3.2. Neurite outgrowth assay
To determine whether curcumin reduced cisplatin-induced
neurite toxicity, two different concentrations of curcumin (1.0 and
10 mg/mL) were added to the cells in combination with cisplatin
(10 mg/mL). The results are expressed as the percentage of neurites
formed in relation to the negative control group, which was
designated as 100%. Curcumin had no effect on the percentage
neurites formed at 1.0 mg/mL or 10 mg/mL (Fig. 2A). However,
strong neurite toxicity was observed with cisplatin treatment,
which decreased the formation of neurites by 62% compared with
the control (Fig. 2B).
Fig. 2. Percentages of neurites in NGF-differentiated PC12 cells after treatment with
(A) curcumin (1.0 or 10 mg/mL) or (B) cisplatin alone (10 mg/mL) or with curcumin
(1.0 or 10 mg/mL). CMN = curcumin and cDDP = cisplatin. Bars indicate the
means  standard deviations obtained from three independent cultures made in
parallel. #Signiﬁcant difference compared with the negative control (p < 0.05), and
*signiﬁcant difference compared with the cDDP (p < 0.05) by paired t-tests.
Fig. 3. RT-qPCR analysis of p53 mRNA transcription of undifferentiated PC12 cells.
Cell cultures were treated with cisplatin (0.1 mg/mL), curcumin (5.0 mg/mL) or a
combination of both compounds for 48 h. CMN = curcumin and cDDP = cisplatin.
Bars indicate the means  standard deviation of the relative expression level using b-
actin as a positive control obtained from three independent cultures made in parallel.
*Signiﬁcant difference compared with the negative control (p < 0.05), as measured by
one-way ANOVA followed by Tukey’s post hoc test.
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cisplatin-induced neurite toxicity. The lower concentration of
curcumin did not result in signiﬁcant protection; however;
curcumin at 10 mg/mL reduced the cisplatin-induced neurite
toxicity by approximately 50%, increasing the percentage of
neurites from 38% to 68%.
3.3. Transcriptional response of the p53 gene
Undifferentiated PC12 cells were treated with non-cytotoxic
concentrations of cisplatin (0.1 mg/mL), curcumin (5.0 mg/mL), or
curcumin combined with cisplatin to evaluate the inﬂuence of p53
gene expression on curcumin’s protective effects. Undifferentiated
PC12 cells were used instead of differentiated PC12 because NGF
differentiation seems to inﬂuence p53 transcription, which could
complicate data interpretation.
Alterations in the transcriptional responses of the p53 gene
were analyzed by RT-qPCR using b-actin as the housekeeping gene.The relative expressions of p53 were calculated with the 2DDct
method by normalizing to the gene expression level of b-actin.
Curcumin did not modulate the transcription of p53 mRNA. The
gene expression results in Fig. 3 show that cisplatin increased the
expression of p53 mRNA approximately twofold. The transcrip-
tional levels of p53 mRNA remained unchanged after treatment of
the cells with curcumin when compared with the control. Similar
transcriptional levels of p53 mRNA were observed after treatment
with cisplatin or cisplatin in combination with curcumin.
4. Discussion
In this study, we investigated the possible protective effects of
curcumin in cisplatin-induced neurotoxicity. The most common
cisplatin-induced neurotoxicity is peripheral neuropathy, which
can be extremely painful, can result in patient suffering, and may
require dose reduction or discontinuation of cisplatin treatment.
Curcumin has been shown to protect normal organs, such as the
liver, kidneys, oral mucosa and heart from chemotherapy- and
radiotherapy-induced toxicity (Goel and Aggarwal, 2010). Al-
though curcumin has been extensively used as a neuroprotective
agent to reduce oxidative damage in neurodegenerative disorders,
its potential to prevent or reduce peripheral neuropathy had not
yet been well evaluated (Huang et al., 2011; Kulkarni and Dhir,
2010). We demonstrated that curcumin attenuates neurite toxicity
induced by cisplatin in the in vitro model of neurotoxicity with the
PC12 cells. Moreover, curcumin did not interfere with the
antitumoral activity of cisplatin as assessed in vitro in HepG2 cells.
Curcumin is generally considered safe and did have showing
considerable toxicity in humans at dosage up to 8 g. The peak
plasma concentration of curcumin in clinical trials of patients
receiving 8 g of curcumin was 0.7 mg/mL; however, healthy human
taking a dose of only 210 mg curcumin in a nanoparticle-based
drug delivery system, reached a maximum plasma concentration
ranging from 0.2 to 0.6 mg/mL (Cheng et al., 2001; Kanai et al.,
2012; Sharma et al., 2005). The concentrations of curcumin used in
the PC12 cells were based on our previously published cell survival
curve (Mendonca et al., 2009). Additionally, the tested concentra-
tions of curcumin, ranging from 0.1 to 10 mg/mL, cover to most
probable in vivo pharmacological active concentrations of curcu-
min (Esatbeyoglu et al., 2012; Gupta et al., 2012).
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tumor types ranges from 50 to 100 mg/m2 of body surface at every
cycle of chemotherapy. Although, the ﬁrst symptoms of peripheral
neuropathy are usually observed after administration of a
cisplatin’s cumulative dose of 250–350 mg/m2 (Argyriou et al.,
2012). Specenier et al. (2009) observed that after an intravenous
administration of cisplatin at a dose of 75 mg/m2, cisplatin reached
a maximum plasma concentration of 4.6 mg/mL. Klein et al. (2007)
showed the, in the PC12 cells, concentrations of cisplatin that
statistically reduced the neurite formation starts from 1.0 mg/mL
and that achieve the greatest effect in reducing neurite outgrowth
at the concentration of 10 mg/mL. In our experiments, cisplatin at a
concentration of 10 mg/mL reduced in 62% the formation of
neurites, and curcumin reduced up to 50% the effect of cisplatin in
the formation of neurites.
The mechanism of neurotoxicity appears to involve damage to
sensory nerve cells of DRG. Morphological changes have been
documented in dorsal root ganglia after platinum drug treatment,
but exactly how the damage occurs is unclear. Analysis of neural
tissues obtained at the time of autopsy from patients treated with
cisplatin showed the DRG as the neural tissue with the greatest
degree of platinum accumulation. Tissue platinum concentrations
in DRG increased with the cumulative dose of cisplatin, and
showed a mean of 1.68 mg/g of tissue. Patients with clinical
evidence of neurotoxicity showed the highest histopathological
neurotoxicity changes and platinum accumulation (Gregg et al.,
1992). Studies in Sprague–Dawley rats treated with 1 mg/kg of
cisplatin for 10 days demonstrated that platinum content was
elevated in sensory DRG isolated from animals compared with
other tissues like heart, muscle, spinal cord and brain. It was also
possible to observe that platinum content in DRG was closely
related with the amount of approximated 0.0075 ng Pt/mg DNA
reported in PC12 cells treated with 2 mg/mL cisplatin for 24 h
(McDonald et al., 2005).
Elucidation of the mechanisms involved in cisplatin peripheral
neuropathy is useful for the identiﬁcation of targets for develop-
ment of effective therapeutic agents for management of such
neurotoxicity. Research has explored and recognized mechanisms,
including mitochondrial dysfunction and ROS generation, which
often lead to axonal damage. In addition to the adduct-forming
direct DNA interaction, cisplatin appears to induce ROS generation
that leads to oxidative stress in several types of cells including
neurons (Jaggi and Singh, 2012). Cisplatin generates superoxide
anions, hydrogen peroxide and hydroxyl radicals that may play a
part in cellular damage, suggesting that antioxidant therapy could
be useful against cisplatin toxicity (Masuda et al., 1994; Santos
et al., 2007).
The use of antioxidants during chemotherapy and radiotherapy
has been a continuing area of interest and discussion. Phytochem-
ical antioxidants, nutritional agents, and synthetic compounds
have been proposed as cytoprotectant agents that may protect
normal tissue from the effects of chemotherapy and radiation
(Block and Gyllenhaal, 2005). Antioxidants, such as acetylcysteine,
amifostine, glutathione and vitamin E, have been proposed as
neuroprotective agents for use in the prevention or limitation of
cisplatin neurotoxicity; however, the clinical data are currently
insufﬁcient to conclude that any of these potential neuroprotec-
tants should be recommended for the prevention of cisplatin-
induced peripheral neuropathy (Albers et al., 2011).
Antioxidant strategies have shown promising neuroprotective
results in pre-clinical studies. Reduced glutathione prevents
cisplatin-induced neuropathy, as measured by sensory nerve
conduction velocity (SNCV) in young adult Wistar rats (Hamers
et al., 1993; Tredici et al., 1994). In primary DRG cultures, alpha-
lipoic acid protects sensory neurons through its antioxidant and
mitochondrial regulatory functions (Melli et al., 2008). Theantioxidant and free radical scavenger amifostine ameliorates
cisplatin-induced neurotoxicity in an NGF-differentiated PC12 cell
in vitro model (Block and Gyllenhaal, 2005; Verstappen et al., 1999,
2004). However, clinical data on these drugs remain controversial,
and their efﬁcacies remain a matter of uncertainty. Although the
lack of efﬁcacy of these compounds has not been elucidated in
clinical trials, this may be the result of pharmacotechnical or
pharmacokinetic thresholds (Argyriou et al., 2006; Klein et al.,
2007).
Curcumin has demonstrated neuroprotective beneﬁts that
extend beyond neuronal diseases. Curcumin protects against
arsenic-induced neurotoxic cholinergic dysfunction in rats and
attenuates peroxynitrite-induced damage in rat spiral ganglion
neurons through its anti-oxidative activity. Curcumin also protects
mitochondria from oxidative stress (Liu et al., 2011; Yadav et al.,
2011). Our previous study demonstrated that curcumin signiﬁ-
cantly reduces the DNA damage induced by cisplatin in PC12 cells
(Mendonca et al., 2009); the current time is the ﬁrst demonstration
that curcumin reduces the toxic effect of cisplatin on PC12 neurite
outgrowth.
Studies have showing that curcumin has neuroprotective
beneﬁts on the DRG. Curcumin reduced the histological changes
of the DRG and sciatic nerve in Wistar rats subjected to sciatic
nerve crush. Curcumin ameliorates the decrease of total number,
diameter, and area of the myelinated nerve ﬁbers after sciatic
nerve injury (Noorafshan et al., 2011). Recently a study in Wistar
rats showed that curcumin reduced the histological changes
induced by cisplatin in the sciatic nerve. Histopathological
examination of sciatic nerve of animals treated with cisplatin
clearly demonstrated degeneration of nerve ﬁber, with reduction
in nerve ﬁber caliber and areas of demyelization. Animal treated
simultaneously with cisplatin and curcumin showed a signiﬁcant
reduction in the sciatic nerve alterations (Al Moundhri et al., 2012).
Our results showed that curcumin protected neurite outgrowth
in non-cytotoxic conditions. Frequently, neurotoxicants present a
signiﬁcant hazard for humans despite low associated cytotoxicity
(Gartlon et al., 2006). Although high levels of Pt–DNA binding is
associated with apoptosis in DRGs in vitro, in conditions with
reduced sensory nerve conduction velocity in the tails of Swiss
albino mice, no DRG neurons are lost after cisplatin treatment.
However, the length of outgrowing axons in DRG explants
decreased (Ozturk et al., 2004; Ta et al., 2006). Thus, sensory
neuron damage may occur even without apoptosis, or cisplatin
damage culminates in neuron apoptosis in only in late stages,
suggesting that anti-apoptotic strategies may be not effective in
reducing peripheral neuropathy.
The use of cytoprotectants has been a subject of controversy
due to their potential to protect malignant tissue. Nevertheless,
studies in cell culture and in rodents have revealed that, in addition
to the protective effects in normal tissue, curcumin can sensitize
tumors to different chemotherapeutic agents including cisplatin
(Goel and Aggarwal, 2010). Thus, we purpose that curcumin may
reduce cisplatin’s neurotoxicity without affecting its antitumor
activity.
Our results indicate that curcumin does not compromise
cisplatin’s antitumor activity. In the MTT assay, curcumin did
not reduce cisplatin’s cytotoxicity in a cancer cell line. HepG2 cells
were chosen for this evaluation because cisplatin is a conventional
drug used for liver cancers. In addition, the combination of
curcumin with cisplatin resulted in synergistic antitumor activity
in the hepatic cancer HA22T/VGH cell line rather than implicating
curcumin in antitumoral failure (Notarbartolo et al., 2005).
We also investigate the impact of curcumin on p53 mRNA
modulation. The p53 tumor suppressor gene is of fundamental
importance in tumor suppression. This gene serves as a cellular
stress sentinel that restricts cellular expansion and eliminates cells
L.M. Mendonc¸a et al. / NeuroToxicology 34 (2013) 205–211210that have encountered acute genotoxic stress (Brady et al., 2011).
The functions of p53 include induction of cell-cycle arrest or
apoptosis in response to acute DNA-damage signals (Vousden and
Lane, 2007; Vousden and Prives, 2009). DNA is the primary target
of cisplatin, which triggers cellular events that culminate in
therapeutically beneﬁcial apoptosis. Loss of p53 function may
attenuate DNA damage-mediated apoptotic signal responses,
which has implications for chemotherapy resistance (Siddik,
2003). Therefore, strategies that diminish cisplatin’s side effects
without compromising p53 function would be broadly valuable for
cancer therapy. Curcumin did not change p53 gene expression;
speciﬁcally, curcumin did not suppress transcription of p53 mRNA.
5. Conclusion
This in vitro study indicates that curcumin has protective effects
against cisplatin-induced neurotoxicity that do not disturb
cisplatin’s therapeutic effect. Curcumin neither suppresses p53
mRNA transcription nor protects tumor cells against cisplatin
cytotoxicity in HepG2 cells. Effective neuroprotective agents could
increase cisplatin therapy effectiveness by reducing adverse effects
and enabling increases the required dosages. Thus, clinical studies
using curcumin to reduce peripheral neuropathy in patients
receiving cisplatin chemotherapy should be considered.
Conﬂict of interest statement
The authors declare that there are no conﬂicts of interest.
Acknowledgments
This study was sponsored by CAPES (Coordenac¸a˜o de Aper-
feic¸oamento de Pessoal de Ensino Superior), CNPq (Conselho
Nacional de Desenvolvimento Cientı´ﬁco e Tecnolo´gico) and FAPESP
(Fundac¸a˜o de Amparo a Pesquisa do Estado de Sa˜o Paulo, process
2008/53947-7). L.M.M. was sponsored by a fellowship from
FAPESP process 2008/10482-4.
References
Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inﬂam-
matory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic,
autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009;41:40–59.
Al Moundhri MS, Al-Salam S, Al Mahrouqee A, Beegam S, Ali BH. The effect of curcumin
on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical,
and histopathological studies. J Med Toxicol 2012. http://dx.doi.org/10.1007/
s13181-012-0239-x PubMed PMID: 22648527.
Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing
neuropathy caused by cisplatin and related compounds. Cochrane Database Syst
Rev 2011. http://dx.doi.org/10.1002/14651858 CD005228. PubMed PMID:
21328275.
Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral
neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012;82:51–77.
Argyriou AA, Chroni E, Koutras A, Iconomou G, Papapetropoulos S, Polychronopoulos P,
et al. A randomized controlled trial evaluating the efﬁcacy and safety of vitamin E
supplementation for protection against cisplatin-induced peripheral neuropathy:
ﬁnal results. Support Care Cancer 2006;14:1134–40.
Barzegar A, Moosavi-Movahedi AA. Intracellular ROS protection efﬁciency and free
radical-scavenging activity of curcumin. PLoS One 2011;6:e26012.
Block KI, Gyllenhaal C. Commentary: the pharmacological antioxidant amifostine –
implications of recent research for integrative cancer care. Integr Cancer Ther
2005;4:329–51.
Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, et al. Distinct p53
transcriptional programs dictate acute DNA-damage responses and tumor sup-
pression. Cell 2011;145:571–83.
Brouwers EE, Huitema AD, Boogerd W, Beijnen JH, Schellens JH. Persistent neuropathy
after treatment with cisplatin and oxaliplatin. Acta Oncol 2009;48:832–41.
Carozzi VA, Marmiroli P, Cavaletti G. The role of oxidative stress and anti-oxidant
treatment in platinum-induced peripheral neurotoxicity. Curr Cancer Drug Targets
2010;10:670–82.
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of
curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant
lesions. Anticancer Res 2001;21:2895–900.Esatbeyoglu T, Huebbe P, Ernst IM, Chin D, Wagner AE, Rimbach G. Curcumin – from
molecule to biological function. Angew Chem Int Ed Engl 2012;51:5308–32.
Gartlon J, Kinsner A, Bal-Price A, Coecke S, Clothier RH. Evaluation of a proposed in vitro
test strategy using neuronal and non-neuronal cell systems for detecting neuro-
toxicity. Toxicol In Vitro 2006;20:1569–81.
Geldof AA, Minneboo A, Heimans JJ. Vinca-alkaloid neurotoxicity measured using an in
vitro model. J Neurooncol 1998;37:109–13.
Goel A, Aggarwal BB. Curcumin the golden spice from Indian saffron, is a chemosensi-
tizer and radiosensitizer for tumors and chemoprotector and radioprotector for
normal organs. Nutr Cancer 2010;62:919–30.
Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as ‘‘Curecumin’’: from kitchen to
clinic. Biochem Pharmacol 2008;75:787–809.
Green S. Validation and in vitro neurotoxicity. Clin Exp Pharmacol Physiol
1995;22:383–4.
Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, et al. Cisplatin
neurotoxicity: the relationship between dosage, time, and platinum concentration
in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol
1992;10:795–803.
Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by turmeric, the
golden spice: from kitchen to clinic. Mol Nutr Food Res 2012. http://dx.doi.org/
10.1002/mnfr.201100741 PubMed PMID: 22887802.
Hamers FP, Brakkee JH, Cavalletti E, Tedeschi M, Marmonti L, Pezzoni G, et al. Reduced
glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res
1993;53:544–9.
Huang HC, Lin CJ, Liu WJ, Jiang RR, Jiang ZF. Dual effects of curcumin on neuronal
oxidative stress in the presence of Cu(II). Food Chem Toxicol 2011;49:1578–83.
Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral
neuropathy. Toxicology 2012;291:1–9.
James SE, Dunham M, Carrion-Jones M, Murashov A, Lu Q. Rho kinase inhibitor Y-27632
facilitates recovery from experimental peripheral neuropathy induced by anti-
cancer drug cisplatin. Neurotoxicology 2010;31:188–94.
Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, et al. Dose–
escalation and pharmacokinetic study of nanoparticle curcumin, a potential anti-
cancer agent with improved bioavailability, in healthy human volunteers. Cancer
Chemother Pharmacol 2012;69:65–70.
Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer
2007;7:573–84.
Klein R, Brown D, Turnley AM. Phenoxodiol protects against cisplatin induced neurite
toxicity in a PC-12 cell model. BMC Neurosci 2007;8:61.
Kulkarni SK, Dhir A. An overview of curcumin in neurological disorders. Indian J Pharm
Sci 2010;72:149–54.
Liu W, Fan Z, Han Y, Lu S, Zhang D, Bai X, et al. Curcumin attenuates peroxynitrite-
induced neurotoxicity in spiral ganglion neurons. Neurotoxicology 2011;32:150–
7.
Ma D, Liu YQ, Xing H, Han XB, Shi XY, Liang FQ, et al. Apoptosis of HeLa cells induced by
cisplatin and its mechanism. J Huazhong U Sci-Med 2008;28:197–9.
Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of
curcumin: a short review. Life Sci 2006;78:2081–7.
Masuda H, Tanaka T, Takahama U. Cisplatin generates superoxide anion by interac-
tion with DNA in a cell-free system. Biochem Biophys Res Commun 1994;203:
1175–80.
McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to
DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for
neurotoxicity. Neurobiol Dis 2005;18:305–13.
Melli G, Taiana M, Camozzi F, Triolo D, Podini P, Quattrini A, et al. Alpha-lipoic acid
prevents mitochondrial damage and neurotoxicity in experimental chemotherapy
neuropathy. Exp Neurol 2008;214:276–84.
Mendonca LM, Dos Santos GC, Antonucci GA, Dos Santos AC, Bianchi Mde L, Antunes
LM. Evaluation of the cytotoxicity and genotoxicity of curcumin in PC12 cells.
Mutat Res 2009;675:29–34.
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to
proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
Noorafshan A, Omidi A, Karbalay-Doust S. Curcumin protects the dorsal root ganglion
and sciatic nerve after crush in rat. Pathol Res Pract 2011;207:577–82.
Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D’Alessandro N. Antitumor
effects of curcumin, alone or in combination with cisplatin or doxorubicin,
on human hepatic cancer cells. Analysis of their possible relationship to changes
in NF-kB activation levels and in IAP gene expression. Cancer Lett 2005;224:
53–65.
Ozturk G, Anlar O, Erdogan E, Kosem M, Ozbek H, Turker A. The effect of Ginkgo extract
EGb761 in cisplatin-induced peripheral neuropathy in mice. Toxicol Appl Phar-
macol 2004;196:169–75.
Pace A, Giannarelli D, Galie E, Savarese A, Carpano S, Della Giulia M, et al. Vitamin E
neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial.
Neurology 2010;74:762–6.
Santos NA, Catao CS, Martins NM, Curti C, Bianchi ML, Santos AC. Cisplatin-induced
nephrotoxicity is associated with oxidative stress, redox state unbalance, im-
pairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch
Toxicol 2007;81:495–504.
Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005;
41:1955–68.
Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance.
Oncogene 2003;22:7265–79.
Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy
deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990;
66:1117–23.
L.M. Mendonc¸a et al. / NeuroToxicology 34 (2013) 205–211 211Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP. Comparative
antioxidant activities of curcumin and its demethoxy and hydrogenated deriva-
tives. Biol Pharm Bull 2007;30:74–8.
Soobrattee MA, Neergheen VS, Luximon-Ramma A, Aruoma OI, Bahorun T. Phenolics as
potential antioxidant therapeutic agents: mechanism and actions. Mutat Res
2005;579:200–13.
Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken JB. Pharmacoki-
netic evaluation of platinum derived from cisplatin administered alone and with
pemetrexed in head and neck cancer patients. Cancer Chemother Pharmacol
2009;64:233–41.
Sreejayan. Rao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm
Pharmacol 1994;46:1013–6.
Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for
dorsal root ganglion neurons correlates with platinum–DNA binding. Neurotox-
icology 2006;27:992–1002.
Takeshita M, Banno Y, Nakamura M, Otsuka M, Teramachi H, Tsuchiya T, et al. The
pivotal role of intracellular calcium in oxaliplatin-induced inhibition of neurite
outgrowth but not cell death in differentiated PC12 cells. Chem Res Toxicol
2011;24:1845–52.
Tischler AS, Greene LA. Morphologic and cytochemical properties of a clonal line of rat
adrenal pheochromocytoma cells which respond to nerve growth factor. Lab Invest
1978;39:77–89.Tredici G, Cavaletti G, Petruccioli MG, Fabbrica D, Tedeschi M, Venturino P. Low-dose
glutathione administration in the prevention of cisplatin-induced peripheral
neuropathy in rats. Neurotoxicology 1994;15:701–4.
Verstappen CC, Geldof AA, Postma TJ, Heimans JJ. In vitro protection from cisplatin-
induced neurotoxicity by amifostine and its metabolite WR1065. J Neurooncol
1999;44:1–5.
Verstappen CC, Postma TJ, Geldof AA, Heimans JJ. Amifostine protects against chemo-
therapy-induced neurotoxicity: an in vitro investigation. Anticancer Res
2004;24:2337–41.
Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275–83.
Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell
2009;137:413–31.
Wang MS, Boddapati S, Emadi S, Sierks MR. Curcumin reduces alpha-synuclein induced
cytotoxicity in Parkinson’s disease cell model. BMC Neurosci 2010;11:57.
Xie L, Li XK, Takahara S. Curcumin has bright prospects for the treatment of multiple
sclerosis. Int Immunopharmacol 2011;11:323–30.
Yadav RS, Chandravanshi LP, Shukla RK, Sankhwar ML, Ansari RW, Shukla PK, et al.
Neuroprotective efﬁcacy of curcumin in arsenic induced cholinergic dysfunctions
in rats. Neurotoxicology 2011;32:760–8.
Zhang K, Chew M, Yang EB, Wong KP, Mack P. Modulation of cisplatin cytotoxicity and
cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-
related mechanisms. Mol Pharmacol 2001;59:837–43.
